Adrian Woolfson
Founder

Adrian is a Co-founder of Replay. Adrian is currently the Co-founder, President & CEO of Genyro, a venture-backed San Diego-based stealth mode NewCo turning biology into a predictive engineering material through AI-guided genome design and Sidewinder, a DNA construction technology enabling complex DNA to be built rapidly and efficiently at scale. Previouly Adrian was the CMO of Nouscom and the Global Clinical Leader of Early and Late Stage Immuno-Oncology/Hematology at Pfizer and held positions of increasing responsibility at Bristol-Myers Squibb in London UK and Princeton, New Jersey. Adrian's undergraduate and post-graduate medical training was in London and Oxford, UK. His PhD and post-doctoral work on molecular immunology in Cambridge, was supervised by Nobel Prize winner, inventor of monoclonal antibodies, and discoverer of CD antigens, César Milstein. He was the Charles and Katharine Darwin Research Fellow at Darwin College Cambridge, a Welcome Trust Clinical Research Fellow, and a National Foundation for Cancer Research Fellow at the MRC Laboratory of Molecular Biology, Cambridge, where he worked on alternative splicing and protein folding. He has authored over 160 publications, including two critically acclaimed books, book chapters, reviews, peer-reviewed scientific papers, and patents addressing I-O therapy, synthetic DNA assembly, immune silencing, synthetic protein refolding machinery, and the barcoding of human diseases using machine learning and soluble immune proteins. He is a regular contributor to The Wall Street Journal and Science magazine and contribute to other publications including: Nature, The Spectator, The New Statesman, Financial Times, Prospect, The Times Literary Supplement, and The Literary Review. He is a a Co-founder, Editorial Board member, and Books Review Editor of the GEN Biotechnology journal. He is on the Board of Singapore- and San Diego-based TCR-T cell therapy company ImmunoScape, and Cambridge, UK-based ProteinLogic. His book, ‘On The Future Of Species’ was published by Bloomsbury on 12 February 2026, the MIT Press on 14 April 2026.